[Biotech&Pharma] Top-Rated Stocks: Zoetis Sees Composite Rating Climb To 96

Browse By

On Tuesday, animal health products maker Zoetis (ZTS) got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96.


{“@context”:”https://schema.org”,”@type”:”VideoObject”,”name”:”How To Find & Track Breakout Stocks”,”description”:”Looking for stocks at or near a new buy point? Regularly check the IBD Breakout Stocks Index.”,”thumbnailUrl”:”https://www.investors.com/wp-content/uploads/2019/04/fIL2dN93-640×360.jpg”,”contentUrl”:”https://cdn.jwplayer.com/manifests/fIL2dN93.m3u8″,”uploadDate”:”2019-04-17T09:04:52+0000″,”duration”:”PT83.11S”,”author”:”Matt Galgani”,”publisher”:{“@type”:”Organization”,”name”:”Investor's Business Daily”,”logo”:{“@type”:”ImageObject”,”url”:”https://www.investors.com/wp-content/uploads/2018/09/ibd-logo.png”},”url”:”https://www.investors.com”},”keywords”:””}

The new rating shows the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. History shows the top market performers tend to have a 95 or higher score as they launch their major moves.

Zoetis is trading about 2% above a 130.30 entry from a flat base.

Looking For Winning Stocks? Try This Simple Routine


The stock sports a 93 EPS Rating, meaning its recent quarterly and annual earnings growth tops 93% of all stocks.

Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.

In Q3, the company posted 13% earnings-per-share growth. Sales growth came in at 7%, down from 9% in the prior quarter.

Zoetis earns the No. 2 rank among its peers in the Medical-Ethical Drugs industry group. Merck (MRK) is the No. 1-ranked stock within the group.


Watch Our Market Experts Spot Top Stocks Each Morning On IBD Live

Which Companies Are Now Outperforming 95% Of All Stocks?

See Which Stocks Just Came On — And Off — IBD's Top Stock Lists

Get Free IBD Newsletters: Market Prep | Tech Report | How To Invest

The post Top-Rated Stocks: Zoetis Sees Composite Rating Climb To 96 appeared first on Investor's Business Daily.

Source Investor’s Business Daily

This news is provided by Investor’s Business Daily RSS Feed, All credits go to Investor’s Business Daily. For more Investor’s Business Daily News please visit: https://www.investors.com/

Disclaimer: All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. The author is not paid to share this information. Cannabis Investment Group is not paid to share this information and has no business relationship other than shareholder with any company whose stock is mentioned in this article.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.